Kemwell Biopharma Pvt Ltd and Avesthagen have signed a Memorandum of Understanding (MoU) that will enable the latter to leverage Kemwell’s biopharmaceutical manufacturing expertise for large scale manufacture of biosimilars. Avesthagen has a portfolio of eight biosimilars under various phases of development in the areas of autoimmune diseases, cancers, anaemia, and cardiovascular disorders.
Kemwell will perform technology transfer, process improvement, scale-up and manufacturing of pre-clinical, clinical and commercial material of Avesthagen biosimilars.
Kemwell’s new 15,000 sq. m. greenfield state-of-the-art facility in Bangalore includes process development labs, a cGMP facility with cell culture capacity of 2 x 2000 liters for drug substance manufacturing, and a cGMP drug product manufacturing facility with vial filling, lyophilization and pre-filled syringes capabilities that would be used for Avesthagen.
Biosimilars are one of the most keenly watched group of pharmaceuticals that are seen as a panacea for the lack of reasonably priced medicines in the developing and developed economies. Many blockbuster and high-priced biologics are to go off-patent in the next decade and biosimilar manufacturers are expected to reap the benefits.
According to Anurag Bagaria, CMD, Kemwell, over the last three decades we have emphasized phases on delivering quality products on time and on a consistent basis. We are looking forward to work for Avesthagen from our new biologics facility and are confident of extending our record of high customer service to this new foray.”
“Kemwell is well placed to accelerate Avesthagen’s projects to get its biosimilars to the global markets. Given the company’s global capabilities in terms of capacities, experience and expertise, we have found a partner that is globally recognized to consistently deliver superior quality product in a timely manner. This enables us to bring our products a step closer to the market, said Dr Villoo Morawala Patell, founder and Chairperson, Avesthagen.